You have not yet registered? Get your account for free.
Forgot Password? We will send you a reset link
30 September 2024
Release according to Article 135, Section 1 BörseG with the objective of Europe-wide distribution
26 September 2024
24 September 2024
Marinomed Biotech AG reports positive clinical results for unique Carragelose eye drops
20 September 2024
Marinomed Biotech AG: Simon Nebel, buy
Marinomed Biotech AG: Andreas Grassauer, buy
Marinomed Biotech AG: Eva Prieschl-Grassauer, buy
18 September 2024
Marinomed Biotech AG resolves capital increase excluding statutory subscription rights by issuing 154,053 no-par value bearer shares at an issue price of EUR 5 per share
15 September 2024
Marinomed Biotech AG sets price range for potential 10% capital increase and potential second capital increase, in each case excluding statutory subscription rights
11 September 2024
Marinomed Biotech AG: First Carragelose products receive new Medical Device Regulation (MDR) certification
2 September 2024
Marinomed Biotech AG evaluates possible 10% capital increase with exclusion of statutory subscription rights
22 August 2024
20 August 2024
Marinomed Biotech AG reports preliminary financial figures for the first half of 2024
14 August 2024
Marinomed Biotech AG: Court opens restructuring proceedings without self-administration
Marinomed Biotech AG aims for financial reorganization by restructuring proceedings without self-administration
13 August 2024
Marinomed Biotech AG applies for court restructuring proceedings without self-administration
14 June 2024
Marinomed Biotech AG secures licensure with leading Consumer Health Care player for the distribution of Carragelose® products in Europe
23 May 2024
Marinomed Biotech AG: Invitation to the 7th Annual General Meeting on Thursday, June 20, 2024, at 13:00 (Vienna time)
22 May 2024
Marinomed Biotech AG announces results for the first quarter of 2024
25 April 2024
Marinomed Biotech AG enters Solv4U R&D collaboration with Brazilian pharmaceutical company Aché Laboratórios
16 April 2024
Marinomed Biotech AG announces results for the 2023 financial year and reports progress with Marinosolv and Carragelose assets
15 April 2024
11 April 2024
Marinomed Biotech AG: Launch of new allergen-blocking Carragelose product in Austria and market entry in Mexico
31 March 2024
Change of total number of voting rights and capital according to article 135 section 1 BörseG
28 March 2024
Marinomed Biotech AG announces agreement with European Investment Bank (EIB) to defer repayments of the 2019 venture loan for 18 months
26 March 2024
Marinomed Biotech AG enters new Carragelose distribution partnerships for Gulf region and Eastern Europe